Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Audit MicroControls’ MicroLQ serum protein control, two levels, is intended to simulate human patient serum samples to monitor the precision of laboratory testing procedures for albumin, alpha1-acid glycoprotein, alpha1-antitrypsin, alpha2-macroglobulin, antithrombin, beta2 microglobulin, ceruloplasmin, complement C3, complement C4, haptoglobin, immunoglobulin A, immunoglobulin E, immunoglobulin G, immunoglobulin M, prealbumin, total protein, and transferrin.
Pathwork Diagnostics has entered into an agreement with Kindstar Global to provide Kindstar with the FDA-cleared IVD kit version of the Pathwork Tissue of Origin Test. The agreement expands Pathwork’s international network of test and service providers and is the first IVD kit agreement for Pathwork.
CellaVision’s proficiency software is for clinical laboratories that assess and perform the classification of blood cells and accredited providers of external quality assessment schemes for laboratory medicine. With the software, medical technologists can train and test their skills in performing peripheral blood and body fluid differential counts and get instant feedback on their performance.
BioFire Diagnostics announced that the U.S. Patent and Trademark Office has issued U.S. patent No. 8,394,608 covering the company’s FilmArray system. This is the first U.S. patent issued to cover the FilmArray system, and BioFire has exclusive rights to the patented technology. The patent specifically covers methods for sample preparation and two-step multiplex polymerase chain reaction in a sealed container.
Hardy Diagnostics’ Val media-fill challenge kits are for USP 797 compliance testing for compounding-sterile preparations (CSPs). The ready-to-use media-fill challenge kits are for use in validating pharmacy compounding personnel in accordance with USP 797 guidelines. Aseptic media-fill testing is part of an effective quality assurance program to ensure pharmaceutical processes and personnel produce sterile products that are free of microbial contaminants.
Randox Laboratories’ Acusera liquid BNP control is for use in the routine monitoring of accuracy and precision. Assayed instrument-specific target values and ranges are provided for Beckman Access, Abbott Architect, and Siemens Advia Centaur instruments. The BNP control is a 100 percent human serum, manufactured to the high-quality standards associated with all Acusera controls.
Life Technologies has signed a collaborative research agreement and related license with Harvard University under which Life Tech has acquired exclusive rights to develop a panel of characterization assays to rapidly evaluate human pluripotent stem cells for their utility in discovery and translational research applications.
Diagnovus has launched Engauge-cancer-DLBCL, a commercial gene-expression assay for risk stratification and treatment of patients with diffuse large B-cell lymphoma. “Engauge-cancer-DLBCL, which combines a patient’s IPI [International Prognostic Index] score and the results of the gene-expression assay, can more accurately predict outcomes for patients than IPI alone in order to optimize treatment choices for patients,” Ron Levy, MD, leader of the Lymphoma Program at Stanford University School of Medicine, said in a statement.
NanoString Technologies has launched its first commercial IVD product, the Prosigna breast cancer prognostic gene signature assay for the nCounter diagnostic system, in the European Union and Israel. Based on the PAM50 gene signature initially discovered by Charles Perou, PhD, and colleagues, the Prosigna assay provides a subtype classification based on the biology of an individual’s breast tumor (intrinsic subtyping), and a prognostic score (risk of recurrence, or ROR, score).
SeraCare Life Sciences has launched three seroconversion panels that provide difficult-to-find patient samples for hepatitis B and HIV. HBV seroconversion panel PHM938 comprises six undiluted plasma samples from a single donor drawn over a six-day period and is HBV DNA-positive from the first bleed.
